Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | NAMPT | P43490 | 10/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | MERTK | Q12866 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099155 | 0.83 | KEAP1 (0.58) | KEAP1NAMPTDYRK1AMERTKMEN1 | |
| SCHEMBL17788633 | 0.83 | KEAP1 (0.58) | KEAP1NAMPTDYRK1AMERTKMEN1 | |
| SCHEMBL19764528 | 0.82 | KEAP1 (0.57) | KEAP1NAMPTDYRK1AMERTKPAK1 | |
| SCHEMBL74518 | 0.80 | KEAP1 (0.68) | KEAP1NAMPTDYRK1AMERTKMEN1 | |
| SCHEMBL17196187 | 0.79 | KEAP1 (0.57) | KEAP1NAMPTDYRK1AMERTKMEN1 | |
| Ammonia Solution, Strong SCHEMBL28922912 | 0.79 | KEAP1 (0.66) | KEAP1NAMPTDYRK1AMERTKMEN1 | |
| SCHEMBL15882447 | 0.78 | NAMPT (0.59) | KEAP1NAMPTRET | |
| SCHEMBL24484881 | 0.77 | KEAP1 (0.64) | KEAP1DYRK1AMERTKMEN1CYP1A2 | |
| SCHEMBL14638413 | 0.77 | KEAP1 (0.68) | KEAP1NAMPTDYRK1AMERTKMEN1 | |
| SCHEMBL6092812 | 0.77 | KEAP1 (1.00) | KEAP1NAMPTDYRK1AMERTKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252151-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | KEAP1 835/4885NAMPT 911/4885DYRK1A 463/4885 |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | KEAP1 35/4885NAMPT 1/4885DYRK1A 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.